(RTTNews) - Precipio Inc. (PRPO), a cancer diagnostics company, on Thursday announced its first quarter financial results.
Q1 2026:
The company reported a net loss of $1.4 million, while in the first quarter of 2025, it reported a net loss of $0.9 million.
Revenues reached $6.71 million, an increase from the $4.93 million recorded a year ago. This includes $6.05 million earned in pathology revenue alone.
Adjusted EBITDA was a loss of $0.16 million in the first quarter, amounting to $1.2 per share, compared to the adjusted EBITDA loss of $0.5 million, or $0.5 per share in the previous year.
Non-GAAP adjusted EBITDA showed an EPS of $0.2 per share, compared to the $0.1 per share recorded for the same in 2025.
PRPO closed Thursday at $28.60, down 0.35%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
